CClinicalTrials.gg
CompletedNCT02756390Updated Dec 11, 2018

CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors

An interventional study of CBTI-CS and Sleep Hygiene in Insomnia, sponsored by Dana-Farber Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-11.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This research study is evaluating the effectiveness of a 3-session behavioral intervention for insomnia in cancer survivors. This is a behavioral intervention study, and no medications are involved.

Read the detailed description

This study is being done to test the usefulness of a 3-session cognitive-behavioral intervention for improving insomnia in cancer survivors. In this study, the investigators are testing whether this 3-session intervention (Cognitive Behavior Therapy for Insomnia in Cancer Survivors: CBTI-CS) will improve insomnia in cancer survivors whose continue to have insomnia symptoms after receiving sleep hygiene education.

In addition to the participants who will be offered sleep hygiene education and the 3-session CBTI-CS,10 additional participants will be recruited to participate in a pilot evaluation of the CBTI-CS intervention delivered via telehealth. This will be a pilot aspect of the study and data from these participants will be for descriptive purposes.

02

Conditions studied

  • Insomnia

Keywords

  • Insomnia cancer Survivor
03

In context

Sleep Initiation and Maintenance Disorders

1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.

This study's enrollment of 56 is below the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Dana-Farber Cancer Institute is the lead sponsor of 813 studies on the registry; 124 are open to participants now.

Of its 113 completed or terminated interventional studies of FDA-regulated products, 77 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

-≥ 18 years of age

  • History of a cancer diagnosis
  • No active cancer therapy (excluding chemoprevention) in the past year, and no cancer therapy planned in the next 6 months
  • No surgery planned in the next 6 months
  • Significant insomnia as evidenced by an Insomnia Severity Index score ≥12
  • Able to read and write in English
  • Willing to attend study group sessions
  • Motivated and able to follow the demands of the CBTI-CS program, to keep sleep records, complete self-report symptom reports and make changes in their sleep schedule, including restricting their sleep.

Exclusion criteria

Exclusion Criteria:

  • Survivors who report ever being diagnosed with Bipolar Disorder will be excluded.
  • Survivors who report ever being diagnosed with a Seizure Disorder or have experienced a seizure in the past 12 months will be excluded.
  • Intention to adjust (decrease or increase) use of sedative, hypnotic, or over-the-counter medications that can affect sleep during the study period.
  • Have diagnosed, untreated sleep apnea, or sleep apnea suspected by a physician but which has not been evaluated, or other sleep disorder
  • Employment that involves irregular sleep patterns, such as shift-work or frequent long-distance travel that involves adjusting to different time zones, or employment in a position that could impact public safety (such as operating heavy machinery)
  • Refusal to modify or reduce excessive alcohol use that is likely to interfere with an individual's sleep.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Arm A (Sleep Hygiene & CBTI-CS)

    Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions

    Behavioral: CBTI-CS · Behavioral: Sleep Hygiene

  • Other
    Arm B (Telehealth Pilot of CBTI-CS)

    Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.

    Behavioral: CBTI-CS via Telehealth

Interventions

  • BehavioralCBTI-CS

    CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.

    Also known as: Cognitive Behavioral Therapy for Insomnia -Cancer Survivors

  • BehavioralSleep Hygiene

    Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.

  • BehavioralCBTI-CS via Telehealth

    The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.

06

What researchers measure

Primary outcomes

  1. The Insomnia Severity Index (ISI)

    The ISI is a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms.

    Time frame: Change from Baseline to 4-weeks post-intervention

Secondary outcomes

  1. Profile of Mood States - Short Form (POMS-SF)

    A 35-item measure which assesses mood states along several dimensions including Total Mood Disturbance.

    Time frame: Change from Baseline to 4 & 8 weeks post-intervention

  2. The Insomnia Severity Index (ISI)

    The ISI is a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms.

    Time frame: Change from Baseline to 8 weeks post-intervention

07

Study locations

1 site
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
08

References and documents

Publications

  • Zhou ES, Partridge AH, Recklitis CJ. A pilot trial of brief group cognitive-behavioral treatment for insomnia in an adult cancer survivorship program. Psychooncology. 2017 Jun;26(6):843-848. doi: 10.1002/pon.4096. Epub 2016 Feb 12. PubMed 26872123 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02756390
Lead sponsor
Dana-Farber Cancer Institute
Collaborators
National Cancer Institute (NCI)
Responsible party
Christopher Recklitis, Ph.D (Christopher Recklitis, PhD, MPH, Dana-Farber Cancer Institute) — Principal investigator
First posted
Apr 29, 2016
Start date
Dec 2015
Primary completion
May 14, 2018
Completion
May 14, 2018
Last update
Dec 11, 2018

Study contacts

Christopher Recklitis, PhD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion